A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

This study is testing icotinib (an EGFR-targeted drug) combined with chemotherapy as a pre-surgery treatment for people with early-stage lung adenocarcinoma that carries a specific EGFR gene mutation. **You may be eligible if...** - You are 18 years or older - You have lung adenocarcinoma confirmed by biopsy within the past 60 days - Your cancer is at clinical stage IIA, IIB, IIIA, or IIIB and is considered surgically removable - Your cancer has a common EGFR mutation (exon 19 deletion or exon 21 L858R) - You have not yet received any treatment for this lung cancer **You may NOT be eligible if...** - Your cancer does not have an EGFR mutation - Your tumor is too advanced to be surgically removed - You have previously received any EGFR-targeted therapy or other cancer treatments - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.